デフォルト表紙
市場調査レポート
商品コード
1065769

リキッドバイオプシーの世界市場:業界動向、シェア、規模、成長、機会、予測(2022年~2027年)

Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 145 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.31円
リキッドバイオプシーの世界市場:業界動向、シェア、規模、成長、機会、予測(2022年~2027年)
出版日: 2022年03月15日
発行: IMARC Services Private Limited
ページ情報: 英文 145 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリキッドバイオプシーの市場規模は、2021年の14億9,000万米ドルから、2027年までに37億米ドルに達し、2022年~2027年の間のCAGRで15.70%の成長が予測されています。

世界中でがん患者の数が急増し、がん診断における高度な低侵襲的(MI)処置に関する個人の意識の高まりとともに、市場を牽引する重要な要因の1つとなっています。さらに、行政当局による研究開発(R&D)活動への資金提供、医療産業の発展への多額の投資が業界企業に有利な成長機会を提供し、デジタルポリメラーゼ連鎖反応(PCR)および次世代シーケンス(NGS)ベースの技術における急速な発展が市場の成長を促すと予測されます。

当レポートでは、世界のリキッドバイオプシー市場について調査分析し、市場概要、市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

第2章 範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のリキッドバイオプシー市場

  • 市場概要
  • 市場実績
  • COVID-19の影響

第6章 市場の内訳:製品およびサービス別

  • キットおよび試薬
  • プラットフォームおよび機器
  • サービス

第7章 市場の内訳:循環バイオマーカー別

  • 循環腫瘍細胞
  • 細胞外小胞
  • 循環腫瘍DNA
  • その他

第8章 市場の内訳:がんの種類別

  • 肺がん
  • 乳がん
  • 結腸直腸がん
  • 前立腺がん
  • 肝臓がん
  • その他

第9章 市場の内訳:エンドユーザー別

  • 病院および研究所
  • 学術・研究センター
  • その他

第10章 市場の内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場の内訳:国別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • ANGLE plc
    • Biocept Inc.
    • Bio-Rad Laboratories Inc
    • Epigenomics AG
    • Exact Sciences Corporation
    • F.Hoffmann-La Roche AG
    • Guardant Health Inc.
    • Illumina Inc.
    • MDxHealth SA
    • Menarini Silicon Biosystems
    • QIAGEN N.V.
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Liquid Biopsy Market: Major Drivers and Challenges
  • Figure 2: Global: Liquid Biopsy Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Liquid Biopsy Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Liquid Biopsy Market: Breakup by Product and Service (in %), 2021
  • Figure 5: Global: Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2021
  • Figure 6: Global: Liquid Biopsy Market: Breakup by Cancer Type (in %), 2021
  • Figure 7: Global: Liquid Biopsy Market: Breakup by End User (in %), 2021
  • Figure 8: Global: Liquid Biopsy Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Liquid Biopsy (Kits and Reagents) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Liquid Biopsy (Kits and Reagents) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Liquid Biopsy (Platforms and Instruments) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Liquid Biopsy (Platforms and Instruments) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Liquid Biopsy (Services) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Liquid Biopsy (Services) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Liquid Biopsy (Circulating Tumor Cells) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Liquid Biopsy (Circulating Tumor Cells) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Liquid Biopsy (Extracellular Vesicles) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Liquid Biopsy (Extracellular Vesicles) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Liquid Biopsy (Circulating Tumor DNA) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Liquid Biopsy (Circulating Tumor DNA) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Liquid Biopsy (Lung Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Liquid Biopsy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Liquid Biopsy (Breast Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Liquid Biopsy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Liquid Biopsy (Colorectal Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Liquid Biopsy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Liquid Biopsy (Prostate Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Liquid Biopsy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Liquid Biopsy (Liver Cancer) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Liquid Biopsy (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Liquid Biopsy (Other Cancer Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Liquid Biopsy (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Liquid Biopsy (Hospitals and Laboratories) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Liquid Biopsy (Hospitals and Laboratories) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Liquid Biopsy (Academic and Research Centers) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Liquid Biopsy (Academic and Research Centers) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: Global: Liquid Biopsy (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: Global: Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: North America: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: North America: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: United States: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: United States: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: Canada: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Canada: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: Asia-Pacific: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: Asia-Pacific: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: China: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: China: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Japan: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Japan: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: India: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: India: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: South Korea: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: South Korea: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: Australia: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: Australia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: Indonesia: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: Indonesia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Europe: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Europe: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: Germany: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: Germany: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: France: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: France: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: United Kingdom: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: United Kingdom: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: Italy: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: Italy: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: Spain: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: Spain: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: Russia: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: Russia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Latin America: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Latin America: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Brazil: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Brazil: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Mexico: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Mexico: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 87: Middle East and Africa: Liquid Biopsy Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 88: Middle East and Africa: Liquid Biopsy Market: Breakup by Country (in %), 2021
  • Figure 89: Middle East and Africa: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 90: Global: Liquid Biopsy Industry: SWOT Analysis
  • Figure 91: Global: Liquid Biopsy Industry: Value Chain Analysis
  • Figure 92: Global: Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liquid Biopsy Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Liquid Biopsy Market Forecast: Breakup by Product and Service (in Million US$), 2022-2027
  • Table 3: Global: Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million US$), 2022-2027
  • Table 4: Global: Liquid Biopsy Market Forecast: Breakup by Cancer Type (in Million US$), 2022-2027
  • Table 5: Global: Liquid Biopsy Market Forecast: Breakup by End User (in Million US$), 2022-2027
  • Table 6: Global: Liquid Biopsy Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Liquid Biopsy Market: Competitive Structure
  • Table 8: Global: Liquid Biopsy Market: Key Players
目次
Product Code: SR0322A39_Report

The global liquid biopsy market reached a value of US$ 1.49 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.7 Billion by 2027 exhibiting a CAGR of 15.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Liquid biopsy is a non-invasive alternative to surgical biopsies enabling doctors to obtain information about a tumor through a blood sample and plan the treatment accordingly. It can reflect changes in tumor gene expression profile and offer a robust base for individualized therapy. It assists in the early diagnosis screening, tumor heterogeneity and drug resistance. Besides this, it also detects epidermal growth factor receptor (EGFR) gene mutations, which occur among patients with non-small cell lung cancer (NSCLC).

Liquid Biopsy Market Trends:

  • Due to sedentary lifestyles and rising tobacco consumption, there is a surge in the number of cancer patients across the globe. This, along with the growing awareness among individuals about advanced minimally invasive (MI) procedures in cancer diagnostics, represents one of the key factors driving the market. Moreover, governing authorities of several countries are financing research and development (R&D) activities to encourage the introduction of advanced cancer solutions. These authorities are also considerable investing in the development of the healthcare industry, which is offering lucrative growth opportunities to industry players. Apart from this, key market players are focusing on product launches to develop personalized medicine worldwide. They are also integrating technological advancements in liquid biopsy to offer better procedure workflow and output. This, coupled with the rising adoption of blood-based biopsy tests for early tumor detection, is positively influencing the market. Additionally, the increasing usage of exosomes for clinical diagnosis in oncology to provide high accuracy and reduced procedural time is catalyzing the demand for liquid biopsy. Growth-inducing factors projected to impel the market growth are rapid development in digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) based technology.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global liquid biopsy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product and service, circulating biomarker, cancer type and end user.

Breakup by Product and Service:

  • Kits and Reagents
  • Platforms and Instruments
  • Services

Breakup by Circulating Biomarker:

  • Circulating Tumor Cells
  • Extracellular Vesicles
  • Circulating Tumor DNA
  • Others

Breakup by Cancer Type:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Others  

Breakup by End User:

  • Hospitals and Laboratories
  • Academic and Research Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V. and Thermo Fisher Scientific Inc. Key Questions Answered in This Report:

  • How has the global liquid biopsy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global liquid biopsy market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product and service?
  • What is the breakup of the market based on the circulating biomarker?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global liquid biopsy market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liquid Biopsy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product and Service

  • 6.1 Kits and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Platforms and Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker

  • 7.1 Circulating Tumor Cells
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Extracellular Vesicles
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Circulating Tumor DNA
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Lung Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Breast Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Prostate Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Liver Cancer
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Laboratories
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Research Centers
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 ANGLE plc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Biocept Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bio-Rad Laboratories Inc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Epigenomics AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Exact Sciences Corporation
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F.Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Guardant Health Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 MDxHealth SA
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Menarini Silicon Biosystems
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 QIAGEN N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis